Investing.com — 周二，H.C. Wainwright分析师Andrew Fein将Unity Biotechnology Inc (NASDAQ: UBX )的目标价从此前的8.00美元大幅下调至4.00美元，同时重申了该公司对该股的买入评级。此次调整是在Unity的药物候选者foselutoclax (UBX1325)用于治疗糖尿病黄斑水肿 ...

Bispecific antibodies (BsAbs) have emerged as a transformative class of biologics, offering dual-targeting mechanisms that enhance therapeutic efficacy across oncology, autoimmune disorders, and ra | ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Doubled the royalty and milestone portfolio to over 120 royalty assets with significant milestone potential through five transactions in 2024 Completed two whole company acquisitions to unlock shareho ...

Doubled the royalty and milestone portfolio to over 120 royalty assets with significant milestone potential through five transactions in ...

Macular degeneration, particularly age-related macular degeneration, is a leading cause of vision loss worldwide. This ...

1 Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China 2 Department of Ophthalmology, Chengdu First People’s Hospital/Chengdu Integrated TCM and Western Medicine Hospital, ...

Faricimab can improve outcomes in patients who experienced poor outcomes with other anti-vascular endothelial growth factor drugs. Patients with treatment-recalcitrant neovascular age-related macular ...

典型的双抗药物如罗氏的Hemlibra（艾美赛珠单抗）、Vabysmo（Faricimab）等，不仅在国际市场上取得了卓越的成绩，甚至在中国市场也展示出强劲的增长态势。2018年，Hemlibra成为国内首款上市的双特异性抗体药物，其全球销售额在2023年达到了49.3亿美元，蕴含着巨大 ...

The following is a summary of “HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TN,” published in the ...